Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755021 | 0.95 | ERN1 (0.52) | ERN1POLBRXFP1KDM4EL3MBTL1 | |
| SCHEMBL3008338 | 0.90 | ERN1 (0.59) | ERN1POLBRXFP1KDM4EL3MBTL1 | |
| SCHEMBL30067006 | 0.90 | ERN1 (0.59) | ERN1POLBRXFP1KDM4EL3MBTL1 | |
| SCHEMBL5755025 | 0.86 | ERN1 (0.52) | ERN1POLBRXFP1KDM4EL3MBTL1 | |
| SCHEMBL6952319 | 0.81 | ERN1 (0.49) | ERN1POLBRXFP1KDM4EL3MBTL1 | |
| SCHEMBL15414637 | 0.80 | ERN1 (0.46) | ERN1POLBRXFP1KDM4EL3MBTL1 | |
| SCHEMBL30067092 | 0.76 | ERN1 (0.46) | ERN1KDM4EMAPTALDH1A1 | |
| SCHEMBL5752881 | 0.76 | RXFP1 (0.50) | ERN1POLBRXFP1KDM4EL3MBTL1 | |
| SCHEMBL8989547 | 0.76 | ERN1 (0.46) | ERN1KDM4EMAPTALDH1A1 | |
| SCHEMBL24075465 | 0.75 | L3MBTL1 (0.50) | ERN1POLBRXFP1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | ERN1 1564/4885POLB 2225/4885RXFP1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.